Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation.

Toxicology and applied pharmacology - 15 Feb 2023

Wang Ying, Liu Qian, Chu Chunhong, Li Lanxin, Wang Zhenxing, Liu Qiyu, Wu Guangyao, Wei Xiangkai, An Lei, Ma Jiguang

Abstract excerpt

Lung cancer, the leading cause of cancer-related mortality, is the most commonly diagnosed cancer. Tyrosine kinase inhibitors (TKIs) are considered a drug-targeted therapy for non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, limited data are available involving the activity of EGFR TKIs against rare EGFR mutations. Here, based on an endogenous EGFR-depleted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 36682591
DOI: 10.1016/j.taap.2023.116385

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation.PMID 36682591Read ↗

Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.Semantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.Semantic proximity Read ↗

A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.Semantic proximity Read ↗

Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors.Semantic proximity Read ↗

Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC.Semantic proximity Read ↗

Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.Semantic proximity Read ↗

Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical reviewSemantic proximity Read ↗

Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.Semantic proximity Read ↗

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.Semantic proximity Read ↗

Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.